|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Lysine-specific demethylase 1 mediates AKT activity and promotes epithelial-mesenchymal transition in PIK3CA mutant colorectal cancer.
|
31704733 |
2020 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.
|
31380280 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
DNA was extracted from the two components of each sample, after microdissection, and characterized for CIMP status and by applying a custom hotspot multigene mutational profiling of 164 hotspot regions of eleven CRC-associated genes (AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN, and TP53).
|
30738693 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
|
31322251 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Lastly, the expression levels of CCND1 and AKT were measured in CRC cell lines.
|
31196027 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our data reveal that DSC3 suppresses CRC cell growth through inhibition of AKT pathway and regulation of E-cadherin.
|
30857973 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis.
|
30983885 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Calcium-Activated Chloride Channel A4 (CLCA4) Plays Inhibitory Roles in Invasion and Migration Through Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Colorectal Cancer.
|
31164625 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Both maintained T-cell responses in peripheral blood to oncogenic driver mutations - BRAF-N581I in the NSCLC and AKT1-E17K in the CRC - years after treatment initiation.
|
30744692 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have previously shown that compound-7g inhibits colorectal cancer cell proliferation and survival by inducing cell cycle arrest and PI3K/AKT/mTOR pathway blockage.
|
31357480 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Polysaccharides from Nostoc commune Vaucher activate macrophages via NF-κB and AKT/JNK1/2 pathways to suppress colorectal cancer growth in vivo.
|
31259992 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In short, COX-2 or 5-LOX deletion and its inhibitors enhanced activity of PTEN and suppressed cell and adenoma progression through PI3K/AKT pathway in colorectal cancer.
|
29339153 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYH9 Promotes Growth and Metastasis via Activation of MAPK/AKT Signaling in Colorectal Cancer.
|
30854093 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer.
|
30858154 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
It has been reported that carcinoma-associated fibroblasts (CAFs) could induce AKT and ERK phosphorylation, and upregulate survivin expression in colorectal cancer (CRC) cells, which could lead to oxaliplatin plus 5-FU resistance.
|
31423282 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Background Resistance to Epidermal Growth Factor inhibition (EGFRi) in patients with KRAS wild-type (wt) Colorectal Cancer (CRC) may occur as a result of PI3K/AKT/mTOR signaling.
|
31506897 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> This study demonstrated that IBC inhibited cell proliferation and induced apoptosis through inhibition of the AKT/GSK-3β/β-catenin pathway in CRC.
|
31118579 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The resultant five core therapeutic targets of Res anti-CRC were identified as protein kinase B1 (AKT1), interleukin 6 (IL6), Tumor protein p53 (TP53), vascular endothelial growth factor, and mitogen-activated protein kinase 1, respectively.
|
30719773 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further screened AI-2-interacting proteins in macrophages using a quantitative proteomics strategy, and evaluated the expression of TNFSF9/TRAF1/p-AKT/IL-1β signaling in cultured macrophages and human colorectal cancer (CRC).
|
31272064 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
LKB1 silencing decreased the phosphorylation of AMP‑activated protein kinase (p‑AMPK) in its downstream pathway, which increased the phosphorylation of protein kinase B (p‑AKT) and promoted tumor cell proliferation, enhancing the migration and invasion of CRC.
|
30483811 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cell signaling pathways essential for CRC progression were then examined, and the phosphorylation levels of AKT, ERK1/2, and STAT3 were found to be decreased by CMTM4 overexpression in SW480 cells and elevated by CMTM4 silencing in HT29 cells.
|
31435638 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
|
30896866 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed that Parathyroid Hormone-related Peptide (PTHrP) induces proliferation, migration, survival and chemoresistance via MAPKs and PI3K/AKT pathways in colorectal cancer (CRC) cells.
|
30639585 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, TMEM206 promoted the development and progression of CRC by enhancing the interactions between the AKT and ERK signaling pathways.
|
30417481 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, CCR6 facilitates tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer.
|
29097259 |
2018 |